Alpha Cognition Inc.
ACOG evidence brief
What we can confirm
- BioSniper Score:
- 4.7 / 10
- Market Cap:
- $193.8M
- Lead Asset:
- alpha-1062 sublingual (Preclinical)
What it means
What to watch
Prepared research question
What matters most for ACOG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ACOG
Alpha Cognition Inc. (ACOG) is a biopharmaceutical company developing and commercializing ZUNVEYL (benzgalantamine), a novel acetylcholinesterase inhibitor for Alzheimer's disease, with a focus on real-world evidence and long-term care settings.
Key risk: Competitive Alzheimer's market
BioSniper Score
Based on 4 of 6 signals
Market Cap
$193.8M
Cash Runway
—
Lead Asset
alpha-1062 sublingual (Preclinical)
Next Catalyst
Patent_Expiry · Jul 23, 2045Tracking 2 pipeline candidates · 1 clinical trial · 1 catalyst · 1 FDA decision for Alpha Cognition Inc..
Alpha Cognition Inc. (ACOG) is a biopharmaceutical company developing and commercializing ZUNVEYL (benzgalantamine), a novel acetylcholinesterase inhibitor for Alzheimer's disease, with a focus on real-world evidence and long-term care settings.
- ZUNVEYL (benzgalantamine) is an oral delayed-release tablet, an acetylcholinesterase inhibitor that also binds neuronal nicotinic receptors (alpha-7 subtype), approved via NDA 505b1 for Alzheimer disease [pipeline].
- Net product revenue from ZUNVEYL was approximately $6 million in Q2 2026, up 71% sequentially from $3.5 million in Q1 2026 [news · published 2026-08-13].
- Initial results from the CONVERGE real-world evidence program, announced October 2026, focused on 180-day titration and concomitant medication patterns among long-term care residents receiving ZUNVEYL [news · published 2026-10-01].
- Alpha Cognition has an exclusive license agreement with CMS International Development and Management Limited (CMSI) for development, manufacturing and commercialization in Asia (excluding Japan), Australia and New Zealand, with total value of $44 million including $3 million upfront and milestone payments, plus royalties [pipeline].
- The company reported positive top-line results from the BEACON real-world study in June 2026, evaluating provider-reported cognitive, behavioral, functional, and tolerability outcomes in long-term care residents with mild to moderate Alzheimer’s disease [news · published 2026-06-09].
What works
- ZUNVEYL revenue is growing rapidly, with net product revenue increasing 71% sequentially from Q1 to Q2 2026, driven by 37% bottle growth and no material stocking benefit [news · published 2026-08-13].
- The company is generating real-world evidence (CONVERGE, BEACON) that may support differentiation on tolerability and titration in long-term care, a key market for Alzheimer’s therapies [news · published 2026-10-01].
- A partnership with CMSI provides a $44 million total deal (including $3 million upfront and milestones) plus royalties for development and commercialization in Asia, Australia, and New Zealand, expanding geographic reach [pipeline].
What to weigh
- ZUNVEYL faces a competitive landscape including Aricept (donepezil), Exelon/Exelon Patch (rivastigmine), Razadyne/Reminyl (galantamine), Adlarity (donepezil transdermal), and Namzaric, all established Alzheimer’s treatments [pipeline].
- Payer implementation has been slower, with downstream PBM implementation unchanged as of Q2 2026, which may limit near-term revenue acceleration [news · published 2026-08-17].
- The company is still in early commercial stage; Q2 2026 net product revenue of $6 million is modest relative to the large Alzheimer’s market, and profitability is not yet established [news · published 2026-08-13].
From the filings
Quoted directly from source documents.
ZUNVEYL is an acetylcholinesterase inhibitor that binds neuronal nicotinic receptors, delivered as an oral delayed-release tablet.
“Acetylcholinesterase inhibitor; binds neuronal nicotinic receptors, most notably the alpha-7 subtype Delivery Vector: ORAL TABLET, DELAYED RELEASE”
Net product revenue in Q2 2026 was $6 million, up 71% from Q1 2026.
“second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer’s treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the first quarter”
News · August 13, 2026
The CONVERGE real-world evidence program analyzed 180-day titration and concomitant medication patterns among long-term care residents receiving ZUNVEYL.
“this analysis focused on 180-day titration and concomitant medication patterns among residents receiving ZUNVEYL (benzgalan”
News · October 1, 2026
Alpha Cognition has an exclusive license with CMSI for Asia, Australia, and New Zealand valued at $44 million total.
“Exclusive license for development, manufacturing and commercialization in Asia (excluding Japan), Australia and New Zealand. Total value $44 million including $3 million upfront and milestone payments, plus royalties.”
Catalyst timeline
- 2045-07-23 · Patent_Expiry · BENZGALANTAMINE GLUCONATE — Patent expiry for NDA218549; if no other exclusivity remains, generic competition could enter the market after this date.
Risks & what to watch (3)›
Key risks
- Competitive Alzheimer's market — ZUNVEYL competes with donepezil, rivastigmine, galantamine, and transdermal donepezil, all established treatments [pipeline].
- Slow payer implementation
- Early commercial stage — Q2 2026 net product revenue of $6 million is modest; profitability not yet established [news · published 2026-08-13].
What to watch
- Further CONVERGE real-world evidence results and their impact on prescriber adoption and payer negotiations [news · published 2026-10-01].
- Revenue growth trajectory and whether sequential increases continue as payer implementation improves [news · published 2026-08-13].
- Competitor developments, including donanemab (Eli Lilly) and EXV-802/EXV-801 (Exciva GmbH) trials in Alzheimer disease [competitor_trial].
- Patent expiry of NDA218549 for benzgalantamine gluconate on 2045-07-23, which could eventually open the market to generics [upcoming catalysts].
Sources: Competitor trials · News · Pipeline · Generated October 7, 2026 · How we verify sources →
Run Alpha Cognition Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Alpha Cognition Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Preclinical
2 candidates
1 upcoming, next in ~6857d
23 buys · 0 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
25
Total value held
$57.8M
| Holder | Shares | Value |
|---|---|---|
| opaleye management inc. | 2,561,950 | $14.1M |
| solas capital management, llc | 1,924,617 | $10.6M |
| awm investment company, inc. | 1,672,168 | $9.2M |
| cable car capital, lp | 1,382,339 | $7.6M |
| ikarian capital, llc | 1,056,259 | $5.8M |
| sphera funds management ltd. | 567,616 | $3.1M |
| alyeska investment group, l.p. | 365,000 | $2.0M |
| boothbay fund management, llc | 256,393 | $1.4M |
| aristides capital llc | 218,510 | $1.2M |
| cantor fitzgerald, l. p. | 188,631 | $1.0M |
Showing top 10 of 25 institutional holders of Alpha Cognition Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 22, 2026- % of float
- 1.6%
- Days to cover
- 5.7
- Shares short
- 327,498
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ACOG short interestGovernance
Frequently asked questions
What is the AI investment thesis for Alpha Cognition Inc.?
Alpha Cognition Inc. (ACOG) is a biopharmaceutical company developing and commercializing ZUNVEYL (benzgalantamine), a novel acetylcholinesterase inhibitor for Alzheimer's disease, with a focus on real-world evidence and long-term care settings.
What is Alpha Cognition Inc.'s lead drug candidate?
Alpha Cognition Inc.'s most advanced tracked candidate is alpha-1062 sublingual (Preclinical) for cognitive impairment with mild traumatic brain injury (mTBI; otherwise known as concussion).
What is Alpha Cognition Inc.'s next catalyst?
Alpha Cognition Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA218549" — expected July 23, 2045.
Who is the CEO of Alpha Cognition Inc.?
Mr. Michael E. McFadden B.B.A. is the chief executive officer of Alpha Cognition Inc. (ACOG).
Where is Alpha Cognition Inc. headquartered?
Alpha Cognition Inc. (ACOG) is headquartered in Grapevine, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.